Provided by Tiger Trade Technology Pte. Ltd.

Perspective Therapeutics

2.67
+0.20888.49%
Volume:1.61M
Turnover:4.03M
Market Cap:304.24M
PE:-2.01
High:2.67
Open:2.43
Low:2.37
Close:2.46
52wk High:6.16
52wk Low:1.96
Shares:114.00M
Float Shares:70.82M
Volume Ratio:0.82
T/O Rate:2.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3300
EPS(LYR):-1.3971
ROE:-39.57%
ROA:-22.28%
PB:0.94
PE(LYR):-1.91

Loading ...

Perspective's Cancer Therapy Candidate Receives FDA Fast Track Designation; Shares Rise Pre-Bell

MT Newswires Live
·
Yesterday

Perspective Therapeutics Wins FDA Fast Track for PSV359

TIPRANKS
·
Yesterday

Perspective Therapeutics Says FDA Grants Fast Track Status for [212Pb]PSV359 in FAP-Positive Solitary Fibrous Tumors

Reuters
·
Yesterday

Perspective Therapeutics Granted Fast Track Designation for [212PB]Psv359 for the Treatment of Adult Patients with Locally Advanced Unresectable And/or Metastatic Fap-Positive Solitary Fibrous Tumors

THOMSON REUTERS
·
Yesterday

Perspective Therapeutics Price Target Maintained with a $14.00/Share by BTIG

Dow Jones
·
Oct 07

Perspective Therapeutics [212Pb]VMT-Α-NET Cohort Safety, Efficacy Data Set for Nanets 2026 Presentation

Reuters
·
Oct 07

Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium

GlobeNewswire
·
Oct 07

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Integra Lifesciences (IART)

TIPRANKS
·
Oct 03

Perspective Therapeutics [212Pb]VMT01 Melanoma Trial Data Set for SITC 2026 Presentation

Reuters
·
Oct 02

Regions, Netflix, Targa, Dynatrace, CATX trending with analysts

TIPRANKS
·
Sep 19

William Blair Initiates Perspective Therapeutics With Outperform Rating

MT Newswires Live
·
Sep 18

Perspective Therapeutics initiated with an Outperform at William Blair

TIPRANKS
·
Sep 18

U.S. Research Roundup-Amrize, Carmax, VF Corp

Reuters
·
Sep 18

Perspective Therapeutics: Merck Collaboration and 2H26 Catalysts Reinforce Buy Rating and Unchanged $11 Price Target

TIPRANKS
·
Sep 15

Perspective Therapeutics Price Target Maintained with a $11.00/Share by Wedbush

Dow Jones
·
Sep 15

Perspective Therapeutics Enters Cancer Clinical Trial Collaboration With Merck; Shares Up Pre-Bell

MT Newswires Live
·
Sep 14

Perspective Therapeutics Partners with Merck to Test [212Pb]PSV359 with Keytruda in FAP-Α-Positive Solid Tumors

Reuters
·
Sep 14

Perspective Therapeutics, - Co Sponsors Study; Merck Provides Pembrolizumab at no Cost

THOMSON REUTERS
·
Sep 14

Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212PB]Psv359 in Combination with Keytruda® (Pembrolizumab) in Fap-Α Positive Solid Tumors

THOMSON REUTERS
·
Sep 14

Perspective Therapeutics [212Pb]VMT-Α-NET Cohort Safety, Efficacy Data Set for ENA Symposium Poster Session

Reuters
·
Sep 11